# A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

> **NCT05366751** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sage Therapeutics** · enrollment: 97 (actual)

## Conditions studied

- Essential Tremor

## Interventions

- **DRUG:** SAGE-324

## Key facts

- **NCT ID:** NCT05366751
- **Lead sponsor:** Sage Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-03
- **Primary completion:** 2024-09-10
- **Final completion:** 2024-09-10
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Internal company decision
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366751, "A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05366751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*